Weizmann Institute (Rehovot, Israel)
The Weizmann Institute of Science (WIS) is at the forefront of research and treatment innovation. The collaboration with Steba biotech led to the formation of Steba Laboratories, a research centre that enables the production and rapid targeting of new compounds prior to an in-depth pre-clinical assessment.
The partnership between WEIZMANN and Steba Laboratories has already resulted in numerous projects and represents a new concept in which Steba biotech, in its capacity as an industrial and commercial partner, has access to university-based innovations at an early stage of the research.
This approach enables the early targeting of candidate compounds for different therapy indications.
As soon as a candidate compound seems to meet the industrial requirements, the WEIZMANN team proceeds with preliminary pre-clinical studies.
At present, two new families of compounds are being studied: one comprises bacteriochlorophyll conjugates with small molecules containing the RGD tripeptide for tumour targeting and the other comprises cationic molecules. The studies concern colorectal cancer and breast cancer, among others, and are based around the improvement of innate and adaptive immunity.
Memorial Sloan Kettering Center (New York, USA)
The collaboration with Memorial Sloan-Kettering, a global leader in cancer research and treatment, initially involved conducting clinical trials and has evolved into an active research and development programme focusing on the treatment of prostate cancers as well as other localized tumours.
The active research and development programme widely benefits from the collaboration between researchers at the Weizmann Institute and the main MSKCC research teams specialised in various cancers.
University of Oxford (Oxford, UK)
Steba Biotech is currently partnering with the University of Oxford and the NIHR (National Institute for Health Research) in the UK to conduct the PART study. PART stands for Partial prostate Ablation versus Radical Treatment and is a landmark randomized trial, comparing TOOKAD to radical prostatectomy or radiotherapy among intermediate risk prostate cancer patients with unilateral disease. The Chief Investigator of PART is Prof. Freddie Hamdy from the University of Oxford, who previously led the ProtecT study.